
A COVID-19 vaccine specifically targeting the Omicron variant would be "prudent" even if it ultimately may not be needed, the top U.S. infectious disease official said on Tuesday as Pfizer Inc and BioNTech SE announced such a clinical trial.
from News-Economic Times https://ift.tt/32vuhRy
via
IFTTT
Comments
Post a Comment